Daily evidence digest

Tocilizumab, vitamin D and COVID-19, bamlanivimab and etesevimab, Victoria’s second wave

Peer reviewed journals featured:

- Systematic reviews on:
  - Tocilizumab in COVID-19 patients [here](#)
  - Diagnostic test accuracy for COVID-19 by mass spectrometry [here](#)
  - Vitamin D levels, vitamin D supplements and COVID-19 [here](#)
- A randomised phase 3 trial of bamlanivimab and etesevimab in high-risk ambulatory COVID-19 patients [here](#)
- A narrative review on how Victoria controlled its second COVID-19 wave [here](#)
- Observational studies on:
  - Association between COVID-19 diagnosis and in-hospital mortality in ST-segment elevation myocardial infarction (STEMI) patients [here](#) and associated editorial [here](#)
  - Rapid antigen test to identify COVID-19 infected patients admitted to the emergency department [here](#)
- Commentary on a US National Institutes of Health summit on anti–SARS-CoV-2 antibodies for COVID-19 [here](#)

Letters and correspondence discussed:

- Evidence and advocacy in Melbourne maternity care during COVID-19 [here](#)
- Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with Johnson & Johnson vaccination [here](#)

Pre-peer review articles featured:

- Cross-border transmissions of Delta substrain AY.29 during Olympic and Paralympic Games [here](#)
- Predictors of COVID-19 testing among Australian youth [here](#)
- A phase 3 trial of the conjugate vaccine, Soberana 02 [here](#)
Guidance and reports

- The Therapeutic Goods Administration (TGA) released information on COVID-19 rapid antigen self-tests (for home use) here and a list of COVID-19 rapid antigen self-tests approved in Australia here.

News and blogs

- FDA puts Spikevax’s (Moderna) paediatric application on hold to investigate side effects here.

Click here to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.